"We entered into an agreement with pSivida US, Inc. (pSivida) in February 2005, which was subsequently amended and restated in March 2008, for the use of fluocinolone acetonide (FAc) in pSivida’s proprietary delivery device. pSivida is a global drug delivery company committed to the biomedical sector and the development of drug delivery products. Our agreement with pSivida provides us with a worldwide exclusive license to develop and sell ILUVIEN, which consists of a tiny polyimide tube with membrane caps that is filled with FAc in a polyvinyl alcohol matrix for delivery to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis). This agreement also provides us with a worldwide non-exclusive license to develop and sell pSivida’s proprietary delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME by delivering a compound to the back of the eye through a direct delivery method through an incision required for a 25-gauge or larger needle. We do not have the right to develop and sell pSivida’s proprietary delivery device for indications for diseases outside of the eye or for the treatment of uveitis. Further, our agreement with pSivida permits pSivida to grant to any other party the right to use its intellectual property (i) to treat DME through an incision smaller than that required for a 25-gauge needle, unless using a corticosteroid delivered to the back of the eye, (ii) to deliver any compound outside the back of the eye unless it is to treat DME through an incision required for a 25-gauge or larger needle, or (iii) to deliver non-corticosteroids to the back of the eye, unless it is to treat DME through an incision required for a 25-gauge or larger needle."
Sentiment: Strong Buy
JD, I remember reading this many times, over and over. This brings up the needle size issue. Which I'm happy to see makes Hernando fricken crazy! Yet, this is pasted from pSivida company issued material. Now I've heard Beverly support Hernando's thesis here, I'm alright with that. But here it is again, haunting investors from both sides. As far as Hernando is concerned, he can just watch the PSDV longs beat him to death with this stuff. It just won't end. We can deliver biologics to the eye.......with no increase in IOP.
Hi Mick, What I get from matrix of the licensing agreement, is that as long as PSDV doesn't use a corticosteroid with a needle size greater than 25 gauge , it can use Durasert or other delivery technologies for DME. Is that how you read it?
Sentiment: Strong Buy